Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
certifying vendors selling proper, noble kava
Specifications First available: 05/2026 Shipping weight: 0.2 kg Product code: NZN-58505 UPC: 8809652585055 Package quantity: 49.979 ml Dimensions: 7.2 x 7 x 5.8 cm , 0.2 kg Other ingredients Water, dipropylene glycol, glycerin, niacinamide, octyldodecanol, helianthus annuus (sunflower) seed oil, butylene glycol, trehalose, pentylene glycol, 1,2-hexanediol, eriobotrya japonica leaf extract, coptis japonica root extract, mentha viridis (spearmint) extract, sodium hyaluronate, theobroma cacao (cocoa) extract, centella asiatica leaf extract, argania spinosa kernel oil, sesamum indicum (sesame) seed oil, chitosan, serenoa serrulata fruit extract, caprylyl methicone, panthenol, polymethylsilsesquioxane, propanediol, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, cetearyl olivate, polyglyceryl-10 behenate/eicosadioate, ammonium acryloyldimethyltaurate/vp copolymer, sorbitan olivate, acrylates/c10-30 alkyl acrylate crosspolymer, tromethamine, ethylhexylglycerin, sorbitan isostearate, adenosine, palmitic acid, hydrogenated lecithin, glutathione, phosphatidylcholine, polyglyceryl-10 laurate, dilauryl thiodipropionate, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, sodium phytate, allantoin, madecassoside, lecithin, cellulose, sodium phosphate, polyglutamic acid, dextrin, asiaticoside, cysteine, tocopherol, 3-o-ethyl ascorbic acid, arbutin, bisabolol, sh-oligopeptide-1, sh-oligopeptide-2, sh-polypeptide-1, sh-polypeptide-10, sh-polypeptide-11, sh-polypeptide-3, sh-polypeptide-59, sh-polypeptide-9, cholesterol, ascorbic acid, beta-sitosterol, ascorbyl glucoside, ceramide np, xanthan gum, c12-16 alcohols
The beneficial effects of GGC on human brain cells may prevent against neurodegeneration by increasing the availability of GSH precursors, which would contribute to the neuroprotective effects of GGC in AD
Dietary intake of magnesium and the risk of epilepsy in middle-aged and older Finnish men: A 22-year follow-up study in a general population
